ACCESS AND SUPPORT
ACCESS AND SUPPORT
Viela VIPs: personal support for you and your patients
Viela VIPs is a complimentary support program for patients, care partners and healthcare professionals. The program offers a team of Nurse Case Managers and Reimbursement Case Managers who will provide:
- One-on-one support
- Help with insurance and coverage
- Financial information and assistance
- Educational resources
Stay up-to-date on Uplizna
Get the latest on Uplizna® (inebilizumab-cdon)—sign up to stay informed:
Thank you for signing up to stay informed about Uplizna® (inebilizumab-cdon)! You’ll be the first to know about any product updates, news and more.
Patient Referral Form
If you and your patient decide Uplizna® (inebilizumab-cdon) is right for them, complete this form with your patient to get them started—it will also serve as their prescription.Download
Patient Referral Form Tip Sheet
Questions about the Patient Referral Form? This tip sheet may help.Download
Efficacy and Safety
Uplizna as a monotherapy was proven to significantly reduce the risk of relapses that can cause permanent disability.Explore the clinical study data
More Resources for Your Patients
Conversation guides and downloadable materials to help inform and educate your patients about Uplizna.See patient resources
Twice-yearly Dosing With Uplizna
Uplizna is the only treatment for neuromyelitis optica spectrum disorder (NMOSD) that is administered twice a year (after initial two start-up doses).Get info about infusions
INDICATION AND IMPORTANT SAFETY INFORMATION
Uplizna® (inebilizumab-cdon) is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
IMPORTANT SAFETY INFORMATION
Uplizna is contraindicated in patients with:
- A history of life-threatening infusion reaction to Uplizna
- Active hepatitis B infection
- Active or untreated latent tuberculosis
WARNINGS AND PRECAUTIONS
Infusion Reactions: Uplizna can cause infusion reactions, which can include headache, nausea, somnolence, dyspnea, fever, myalgia, rash, or other symptoms. Infusion reactions were most common with the first infusion but were also observed during subsequent infusions. Administer pre-medication with a corticosteroid, an antihistamine, and an anti-pyretic.
Infections: The most common infections reported by Uplizna-treated patients in the randomized and open-label periods included urinary tract infection (20%), nasopharyngitis (13%), upper respiratory tract infection (8%), and influenza (7%). Delay Uplizna administration in patients with an active infection until the infection is resolved.
Increased immunosuppressive effects are possible if combining Uplizna with another immunosuppressive therapy.
The risk of hepatitis B virus (HBV) reactivation has been observed with other B-cell-depleting antibodies. Perform HBV screening in all patients before initiation of treatment with Uplizna. Do not administer to patients with active hepatitis.
Although no confirmed cases of Progressive Multifocal Leukoencephalopathy (PML) were identified in Uplizna clinical trials, JC virus infection resulting in PML has been observed in patients treated with other B-cell-depleting antibodies and other therapies that affect immune competence. At the first sign or symptom suggestive of PML, withhold Uplizna and perform an appropriate diagnostic evaluation.
Patients should be evaluated for tuberculosis risk factors and tested for latent infection prior to initiating Uplizna.
Vaccination with live-attenuated or live vaccines is not recommended during treatment and after discontinuation, until B-cell repletion.
Reduction in Immunoglobulins: There may be a progressive and prolonged hypogammaglobulinemia or decline in the levels of total and individual immunoglobulins such as immunoglobulins G and M (IgG and IgM) with continued Uplizna treatment. Monitor the level of immunoglobulins at the beginning, during, and after discontinuation of treatment with Uplizna until B-cell repletion especially in patients with opportunistic or recurrent infections.
Fetal Risk: May cause fetal harm based on animal data. Advise females of reproductive potential of the potential risk to a fetus and to use an effective method of contraception during treatment and for 6 months after stopping Uplizna.
Adverse Reactions: The most common adverse reactions (at least 10% of patients treated with Uplizna and greater than placebo) were urinary tract infection and arthralgia.